Plasma metabolites and six multimorbidity trajectories in Japanese adults aged 40+
In 7199 Tsuruoka cohort adults aged 40 and over, baseline fasting plasma metabolites were related to six claims-based trajectories of newly documented disease burden over 60 months; 19 metabolites were associated with trajectory severity, and the authors call for replication. [1]
Automatic summary · not editorially reviewed
The key findings
The Tsuruoka Metabolomics Cohort Study in Japan analysed 7199 adults aged 40 and over with baseline fasting plasma metabolomics of 94 metabolites and linked health insurance claims, building monthly cumulative Charlson Comorbidity Index scores from cohort entry to 60 months. [1]
K-means clustering identified six trajectories of claims-recorded disease burden, and after false discovery rate correction 19 metabolites were associated with greater trajectory severity; glutamate had the strongest positive association (odds ratio 1.18 per standard deviation, 95% confidence interval 1.12–1.24). [1]
The authors describe amino acid metabolism, redox balance and microbiome-host interactions as candidate pathways and state that replication in independent cohorts is warranted. [1]
The source at a glance
- Study type / format
- Population-based cohort study (abstract).
- Population / context
- 7199 adults aged 40 years and over in the Tsuruoka Metabolomics Cohort Study, Japan.
- Summary based on
- Study abstract
- Original publication
- July 18, 2026
Tsuruoka cohort: baseline metabolites, claims-based trajectories
The population-based Tsuruoka Metabolomics Cohort Study in Japan included 7199 adults aged 40 years and over. At baseline, fasting plasma was measured for 94 metabolites by capillary electrophoresis-mass spectrometry, and health insurance claims were linked. From aligned cohort entry to 60 months, monthly cumulative Charlson Comorbidity Index scores were built to capture newly documented Charlson conditions after follow-up start. K-means clustering sorted participants into six trajectories of claims-recorded disease burden, ranging from minimal accumulation to rapid progression.
Supporting source [1]
Nineteen metabolites linked to trajectory severity
Ordinal logistic regression related metabolites to ordered trajectory severity, adjusted for demographic and lifestyle factors. After false discovery rate correction, 19 metabolites were associated with greater trajectory severity. Glutamate showed the strongest positive association (odds ratio 1.18 per standard deviation; 95% confidence interval 1.12–1.24), while cysteine-glutathione disulfide showed the strongest inverse association (odds ratio 0.89; 95% confidence interval 0.86–0.93). Eighteen of these metabolites were also associated with time to first newly documented Charlson disease. Disease-specific analyses linked glutamate to diabetes with complications, mild liver disease and cerebrovascular disease; exploratory cluster-specific analyses identified hippurate as a distinctive marker of a late-acceleration trajectory.
Supporting source [1]
Candidate pathways, not established causes
The authors interpret these findings as implicating amino acid metabolism, redox balance and microbiome-host interactions as candidate biological pathways behind heterogeneous patterns of age-related disease accumulation. They state that replication in independent cohorts is warranted and that the signals may inform biomarker development for accelerated disease-burden accumulation. The associations are observational and do not show that any metabolite causes disease accumulation; the abstract reports no causal analysis.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. This is an observational cohort study, so the metabolite associations are not causal. Trajectories rest on insurance claims and the Charlson index, and the abstract reports no follow-up beyond 60 months. Cluster-specific analyses are described as exploratory, and the authors call for replication in independent cohorts.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Toki R, Iba C, Omoto Y, Matsumoto M, Iida M, Edagawa S, Harada S, Hirata A, Miyagawa N, Miyake A, Hirayama A, Sugimoto M, Sato A, Amano K, Soga T, Arakawa K, Takebayashi T. · europepmc.org · July 18, 2026